About GeneTx
GeneTx is a company based in Sarasota (United States) founded in 2017 by Allyson Berent and Paula Evans was acquired by Ultragenyx in July 2022.. GeneTx has raised $20 million across 1 funding round from investors including Ultragenyx. GeneTx offers products and services including DTX401, DTX301, UX701, UX143, and GTX-102. GeneTx operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Sarasota, United States
- Founders Allyson Berent, Paula Evans
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ultragenyx Pharmaceutical Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$20 M (USD)
in 1 rounds
-
Latest Funding Round
$20 M (USD), Series A
Aug 15, 2019
- Investors
-
Employee Count
Employee Count
-
Acquired by
Ultragenyx
(Jul 18, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GeneTx
GeneTx offers a comprehensive portfolio of products and services, including DTX401, DTX301, UX701, UX143, and GTX-102. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for glycogen storage disease type Ia
Therapy for ornithine transcarbamylase deficiency
Treatment targeting Wilson disease symptoms
Addresses osteogenesis imperfecta conditions
Therapy for Angelman syndrome patients
Unlock access to complete
Unlock access to complete
Leadership Team
237 people
Software Development Team
107 people
Operations Team
49 people
Senior Team
48 people
Product Management Team
43 people
Legal and Compliance
23 people
Ultracare Team
16 people
Human Resources and Administration
14 people
Unlock access to complete
Funding Insights of GeneTx
GeneTx has successfully raised a total of $20M through 1 strategic funding round. The most recent funding activity was a Series A round of $20 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $20.0M
-
First Round
First Round
(15 Aug 2019)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2019 | Amount | Series A - GeneTx | Valuation | Ultragenyx |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in GeneTx
GeneTx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ultragenyx. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GeneTx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - GeneTx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genetx Comparisons
Competitors of GeneTx
GeneTx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genetx
Frequently Asked Questions about GeneTx
When was GeneTx founded?
GeneTx was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is GeneTx located?
GeneTx is headquartered in Sarasota, United States. It is registered at Sarasota, Florida, United States.
Who is the current CEO of GeneTx?
Paula Evans is the current CEO of GeneTx. They have also founded this company.
Is GeneTx a funded company?
GeneTx is a funded company, having raised a total of $20M across 1 funding round to date. The company's 1st funding round was a Series A of $20M, raised on Aug 15, 2019.
What does GeneTx do?
GeneTx Biothereputics (a subsidiary of the Foundation for Angelman Syndrome Therapeutics) is developing therapeutics for treating Angelman syndrome (AS). The company has developed GTX-102, an antisense oligonucleotide which is used for targeted therapy for treating the rare genetic disorder that causes developmental delay, impaired motor function, loss of speech, and epilepsy.
Who are the top competitors of GeneTx?
GeneTx's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does GeneTx offer?
GeneTx offers DTX401, DTX301, UX701, UX143, and GTX-102.
Who are GeneTx's investors?
GeneTx has 1 investor. Key investors include Ultragenyx.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.